Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Overweight 1Obesity 1Melanoma 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Carboplatin 4Trastuzumab 3Cyclophosphamide 3Paclitaxel 2Letrozole 2Fulvestrant 2Docetaxel 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1entrectinib 1Vorinostat 1Vinorelbine 1Thiotepa 1Taxes 1Tamoxifen 1Sugars 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Naltrexone 1Melphalan 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Liquid Biopsy 1High-Energy Shock Waves 1Goserelin 1Fluorine-18 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Lobular × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡